Foretinib is an experimental drug candidate for the treatment of cancer. It was discovered by Exelixis and is under development by GlaxoSmithKline. It is currently in Phase II clinical trials. {As of |2012|12} no phase III trials are registered. Foretinib is an inhibitor of the kinase enzymes c-Met and vascular endothelial growth factor receptor 2...
Found on


A substance being studied in the treatment of cancer. Foretinib blocks enzymes involved in the growth and spread of tumor cells. It may also prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called MET/VEGFR-2 inhibitor GSK1363089 and XL880.
Found on
No exact match found